1.Mahfouz AE，Hamm B，Taupitz M. Contrast agents for MR imaging of the liver：A clinical overview. European Radiology，1997，7：507-513.

2.Hahn PF，Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am，1998，36：287-297.

3.Semelka RC，Helmberger TK. Contrast agents for MR imaging of the liver. Radiology，2001，218：27-38.

4.冯志明，马俊．钆螯合物磁共振成像对比剂的研究进展．国际生物医学工程杂志，2006，29（4）：231-234.

5.Vogl TJ，Kummel S，Hammerstingl R，et al. Liver tumors：Comparison of MR imaging with Gd-EOB-DTPA and Gd- DTPA.Radiology，1996，200：59-71.

6.Seale MK，Catalano OA，Saini S，et al. Hepatobiliary-speci fi c MR contrast agents：role in imaging the liver and biliary tree.Radiographics，2009，29：S725-748.

7.Mayo-Smith WW，Saini S，Slater G，et al. MR contrast material for vascular enhancement：Value of superparamagnetic iron oxide. Am J Roentgenol，1996，166：73-80.

8.吴静云，王可，郭小超，等．肝脏MR动态增强扫描：Gd-EOB-DTPA与Gd-DTPA的个体内对照研究．放射学实践，2016，31（4）：326-330.

9.Duda S，Laniado M，Kopp A，et al. Superparamagnetic iron oxide：detection of focal liver lesions at high- fi eld-strength MR imaging. JMRI，1994，4：309-314.

10.Saito K，Shindo H，Ozuki T，et al. Perfusion study hypervascular hepatocellular carcinoma with SPIO. Magnetic Resonance in Medical Sciences，2005，4：151-158.

11.Rummeny EJ，Torres CG，Kurdziel JC，et al. Mn-DPDP for MR imaging of the liver：results of an independent image evaluation of the European phase III studies. Acta Radiol，1997，38：638- 642.

12.Tirone P，Castano M，Cipolla P，et al. General pharmacology in experimental animals of gadobenate dimeglumine（MultiHance）：a new magnetic resonance imaging contrast agent. J Comput Assist Tomogr，1999，23：S195-206.

13.Manfredi R，Maresca G，Baron RL，et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine（Gd-BOPTA）．J Magn Reson Imaging，1999，9：704-710.

14.Grazioli L，Morana G，Federle MP，et al. Focal nodular hyperplasia：Morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology，2001，221：731-739.

15.Ba-Ssalamah A，Uffmann M，Saini S，et al. Clinical value of MRI liver-speci fi c contrast agents：a tailored examination for a con fi dent non-invasive diagnosis of focal liver lesions. Eur Radiol，2009，19：342-357.

16.Pintaske J，Martirosian P，Gra SH，et al. Relaxivity of gadopentetate dimeglumine（Magnevist），gadobutrol（Gadovist）and gadobenate dimeglumine（MultiHance）in human blood plasma at 0.2，1.5 and 5 Teslar. Invest Radiol，2006，41：213-221.

17.Dahlqvist Leinhard O1，Dahlström N，Kihlberg J，et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA：apilot study. Eur Radiol，2012，22：642-653.

18.Motosugi U，Ichikawa T，Sou H，et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging：which biological markers of the liver function affect the enhancement? J Magn Reson Imaging，2009，30：1042-1046.

19.Filippone A，Blakeborough A，Breuer J，et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media：a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging，2010，31：356-364.

20.Tamada T，Ito K，Sone T，et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel：comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging，2009，29：636-640.

21.张澍杰，饶圣祥，陈锦，等．Gd-EOB-DTPA与Gd-DTPA增强MR对肝硬化患者肝血管和肝实质增强效果的自身对照研究．放射学实践，2014，29（7）：814-817.

22.Tamada T，Ito K，Higaki A，et al. Gd-EOB-DTPA-enhanced MR imaging：evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol，2011，80：e311-e316.

23.Pietryga JA，Burke LM，Marin D，et al. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium：examination recovery with a multiple arterial phase acquisition. Radiology，2014，271：426-434.

24.Davenport MS，Viglianti BL，Al-Hawary MM，et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine：effect on arterial phase image quality. Radiology，2013，266：452-461.